Radiation plus experimental nuclear medicine for high-risk prostate cancer
Part of Cancer clinical trials.
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with high-risk prostate cancer with exactly one major risk factor (large tumor, aggressive grade, or high PSA level)
- Cancer confirmed by biopsy to be adenocarcinoma and must show up very brightly on a special PET scan
- Cancer hasn't spread to distant organs or enlarged lymph nodes outside the pelvis
- Eligible for and willing to receive radiation therapy and hormone therapy
- Blood work and organ function tests from the past 6 weeks show healthy bone marrow and kidneys
- No prior cancer treatment except up to 45 days of hormone therapy, and able to use condoms for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.
Hear when a new High-Risk Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.